Ultragenyx Q3 2020 Earnings Report
Key Takeaways
Ultragenyx reported Q3 2020 total revenue of $81.5 million, driven by Crysvita revenue of $37.3 million. The company has increased the lower end of Crysvita guidance range; updated full year range is $130 million to $140 million. Dojolvi launch is off to a strong start.
Crysvita continues to deliver meaningful revenue growth.
Dojolvi launch off to a strong start.
Angelman program with GeneTx read out very promising, early data.
Strategic collaboration with Solid Biosciences adds an important potential Duchenne therapy to preclinical pipeline.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Forward Guidance
The lower end of the range for 2020 Crysvita revenue in Ultragenyx territories1 has been increased to $130.0 million from $125.0 million. The updated guidance range is $130.0 million to $140.0 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income